Enhancement of an Auto-Injector Device for Self-Administration of Etanercept in Patients With Rheumatoid Arthritis Confers Emotional and Functional Benefits
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2198-6584
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Enhancement of an Auto-Injector Device for Self-Administration of Etanercept in Patients With Rheumatoid Arthritis Confers Emotional and Functional Benefits ; volume:7 ; number:3 ; day:4 ; month:6 ; year:2020 ; pages:537-552 ; date:9.2020
Rheumatology and therapy ; 7, Heft 3 (4.6.2020), 537-552, 9.2020
- Creator
-
Rekaya, Naceur
Vicik, Steven M.
Hulesch, Bors T.
McDonald, Laura L.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40744-020-00216-5
- URN
-
urn:nbn:de:101:1-2020100122272895532349
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rekaya, Naceur
- Vicik, Steven M.
- Hulesch, Bors T.
- McDonald, Laura L.
- SpringerLink (Online service)
Other Objects (12)
Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis
Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe
Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe
Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
SCHICK EVERSHARP INJECTOR RAZOR
Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept
Clinical and economic efficiency to reduce dose etanercept and adalimumab in patients with rheumatoid arthritis
Correction to: The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis
Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe
Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe
Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
SCHICK EVERSHARP INJECTOR RAZOR
Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept
Clinical and economic efficiency to reduce dose etanercept and adalimumab in patients with rheumatoid arthritis
Correction to: The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis
Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe
Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe
Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
SCHICK EVERSHARP INJECTOR RAZOR
Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept
Clinical and economic efficiency to reduce dose etanercept and adalimumab in patients with rheumatoid arthritis